Literature DB >> 28522215

Blocking voltage-gated sodium channels as a strategy to suppress pathological cough.

Hui Sun1, Marian Kollarik1, Bradley J Undem2.   

Abstract

Pathological cough is thought to be secondary to inappropriate activation of vagal sensory nerves. Sensory nerves can be activated by a large number of disparate stimuli. The most relevant stimuli to block for effective anti-tussive therapy likely depend on the specific underlying pathology that is leading to the coughing. Blocking voltage-gated sodium channels (NaV) will prevent action potential initiation and conduction and therefore prevent sensory communication between the airways and brainstem. In so doing, they would be expected to inhibit evoked cough independently of the nature of the stimulus and underlying pathology. There are nine subtypes of NaVs each with distinct pore-forming alpha subunits referred to NaV1.1-1.9. Among these channels, based on functional and genetic analysis of cough causing vagal afferent nerve subtypes, we hypothesize that targeting NaV1.7 and NaV1.8 is a rational strategy forward for the effective treatment of pathological cough.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28522215     DOI: 10.1016/j.pupt.2017.05.010

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  8 in total

1.  Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker.

Authors:  Ivan Tochitsky; Sooyeon Jo; Nick Andrews; Masakazu Kotoda; Benjamin Doyle; Jaehoon Shim; Sebastien Talbot; David Roberson; Jinbo Lee; Louise Haste; Stephen M Jordan; Bruce D Levy; Bruce P Bean; Clifford J Woolf
Journal:  Br J Pharmacol       Date:  2021-06-21       Impact factor: 9.473

Review 2.  The NaV1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons.

Authors:  Tânia C Gonçalves; Evelyne Benoit; Michel Partiseti; Denis Servent
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

3.  Prostaglandin E2 sensitizes the cough reflex centrally via EP3 receptor-dependent activation of NaV 1.8 channels.

Authors:  Al-Shaimaa A Al-Kandery; Muddanna S Rao; Ahmed Z El-Hashim
Journal:  Respir Res       Date:  2021-11-18

4.  Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough.

Authors:  Pranav Gupta; Azher Hussain; Anthony P Ford; Steven Smith; Jesse C Nussbaum; Aubrey Stoch; Marian Iwamoto
Journal:  Clin Pharmacol Drug Dev       Date:  2022-05-05

5.  In Vivo Documentation of Stimulus Velocity Tuning of Mechanically Induced Reflex Cough.

Authors:  B Demoulin; L Coutier-Marie; I Ioan; C E Schweitzer; L Foucauld; S Demoulin-Alexikova
Journal:  Physiol Res       Date:  2020-03-27       Impact factor: 1.881

Review 6.  The Prospect for Potent Sodium Voltage-Gated Channel Blockers to Relieve an Excessive Cough.

Authors:  M Brozmanova; N Pavelkova
Journal:  Physiol Res       Date:  2020-03-27       Impact factor: 1.881

7.  Modulation of protective reflex cough by acute immune driven inflammation of lower airways in anesthetized rabbits.

Authors:  Laurent Foucaud; Bruno Demoulin; Anne-Laure Leblanc; Iulia Ioan; Cyril Schweitzer; Silvia Demoulin-Alexikova
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

Review 8.  Tetrodotoxin: A New Strategy to Treat Visceral Pain?

Authors:  Ana Campos-Ríos; Lola Rueda-Ruzafa; Salvador Herrera-Pérez; Paula Rivas-Ramírez; José Antonio Lamas
Journal:  Toxins (Basel)       Date:  2021-07-16       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.